Given that LBH589 shows anticancer activity in preclinical pancreatic cancer models [28] as well that the tumor-selective TRAIL is a potential cancer therapeutic protein and is being tested in phase I clinical trials, our findings warrant further evaluation on the combination of LBH589 and TRAIL as a potential therapeutic regimens against pancreatic cancer in animal models and in clinical trials. Here, TNFSF10 is linked to neoplasm.